Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The effect of ablation sequence and duration on lesion shape using rapidly pulsed radiofrequency energy through multiple electrodes.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2000

Same author

The 1.3 A crystal structure of a biotin-binding pseudoknot and the basis for RNA molecular recognition.

Journal of molecular biology·2000

Same author

Therapeutic approaches to the management of common baldness.

International journal of clinical practice·2000

Same author

Evidence for evolutionarily conserved secondary structure in the H19 tumor suppressor RNA.

Nucleic acids research·2000

Same author

The value and impact of violence prevention training in a home healthcare setting.

Home healthcare nurse manager·2000

Same author

The structural basis for molecular recognition by the vitamin B 12 RNA aptamer.

Nature structural biology·2000

Search research articles

Related Experiment Video

Updated: May 30, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Adjuvant therapy with bone-targeted agents.

C Wilson¹, R E Coleman

¹Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.

Current Opinion in Supportive and Palliative Care

|July 26, 2011

Summary

This summary is machine-generated.

Bone-targeting agents effectively prevent chemotherapy-induced bone loss (CTIBL) in breast cancer and reduce fractures in prostate cancer. Their role in preventing cancer metastasis requires further investigation.

More Related Videos

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Related Experiment Videos

Last Updated: May 30, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Area of Science:

Oncology
Pharmacology
Bone Metabolism

Background:

Bone-targeting agents are used in adjuvant cancer therapy to prevent chemotherapy-induced bone loss (CTIBL) and inhibit metastasis.
Recent advances focus on bisphosphonates and denosumab for these indications.

Purpose of the Study:

To review recent advances in the use of bone-targeting agents for CTIBL prevention and metastasis inhibition in cancer patients.
To evaluate the efficacy and consistency of findings from clinical trials.

Main Methods:

Review of randomized controlled trials and clinical guidelines.
Analysis of data on bisphosphonates and denosumab in breast and prostate cancer.

Main Results:

Bisphosphonates are established for CTIBL prevention in breast cancer, informing guidelines.
Denosumab shows efficacy in preventing bone loss and fractures in prostate cancer.
Evidence for bone-targeting agents in metastasis prevention is inconsistent across studies.

Conclusions:

The role of bisphosphonates in CTIBL is defined for breast cancer; more evidence is needed for other malignancies.
Ongoing studies will clarify patient populations benefiting from metastasis prevention strategies.
Denosumab offers an alternative adjuvant therapy; combination therapies require investigation.